Locations:
Search IconSearch
April 20, 2020/Cancer/News & Insight

How to Continue Caring for Cancer Patients During the Pandemic

Advice from the leader of Cleveland Clinic Cancer Center

Cleveland-Clinic_Taussig_DuskFacade_FromSouthWest-650×433

In spite of the challenges posed by the novel coronavirus pandemic, it is essential that patients with suspected, newly diagnosed or progressive cancers receive ongoing care.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Cleveland Clinic Cancer Center has continued to provide consultation and treatment during the pandemic, utilizing virtual visits and, when necessary, in-person clinical care with appropriate precautions.

In addition to serving patients in our own healthcare system, the cancer center has connected with oncologists in regions hard-hit by COVID-19 who have had to defer or delay cancer treatments, to offer temporary care until conditions improve and patients can resume seeing their own physicians. (Oncologists in need of this assistance should call Cleveland Clinic’s Cancer Answer Line, 866.223.8100.)

How is it possible to maintain patient services during this difficult time? The key is taking care of the cancer center’s workforce so they can care for others, says Cleveland Clinic Taussig Cancer Institute Chair Brian J. Bolwell, MD. That means addressing fears, sharing information regularly and transparently, and providing the support and encouragement people need to do their jobs.

Learn more about Dr. Bolwell’s approach to leading the cancer center and providing care during COVID-19 by reading his latest column in Oncology Times. In addition to heading Cleveland Clinic Cancer Center, Dr. Bolwell is Cleveland Clinic’s Director of Physician Leadership and Development.

Advertisement

Related Articles

AML cells in blood flow
July 10, 2026/Cancer/Blood Cancers

Ziftomenib + Chemotherapy Drives Deep Remission in Frontline NPM1-m/KMT2A-r AML

Combination therapy may soon represent new standard of care

Researcher with microscope
June 26, 2026/Cancer

Testosterone May Offer Anti-Tumor Activity in Glioblastoma

Research findings offer clues for improving disease outcomes in men

Male patient with doctor
June 17, 2026/Cancer/Patient Support

Overcoming Taboos: Helping Men with Cancer Restore Sexual Health

Creating a safe space for patients

Masked patient with physician
June 15, 2026/Cancer/Patient Support

Managing Infection Risk in the Era of Cell Therapy

Long-term immune effects reshape preventative strategies and timelines

Immune checkpoint inhibitor illustration
June 12, 2026/Cancer/News & Insight

Immunotherapy Appears to Reduce the Risk of Secondary Primary Cancers

Large-scale database also reveals potential for immunotherapy to protect against cancer

T53 mutation illustration
June 10, 2026/Cancer/News & Insight

TP53 Mutation Acquisition Timing Influences Prognosis in Myeloproliferative Neoplasms

Findings may help guide discussions around prognosis and allogeneic stem cell transplantation

Woman consoling another
June 5, 2026/Cancer/Blood Cancers

Equal Access to Modern Therapy May Help Eliminate Survival Differences in Multiple Myeloma

Research underscores the importance of access to timely diagnosis and treatment in this patient population.

Multiple myeloma cells
June 4, 2026/Cancer/Blood Cancers

Machine Learning Model Outperforms Standard Risk Tools for Multiple Myeloma

A Cleveland Clinic model combining clinical staging, genomics and AI predicts survival with 18% greater accuracy — and could help match patients to more effective treatments.

Ad